The Latin America, Middle East and Africa Pneumonia Vaccines Market would witness market growth of 10.1% CAGR during the forecast period (2019-2025). Pneumonia is a disease that causes lung contamination occurring in one or both the lungs caused by bacterial organisms, viruses, or fungi; bacterial pneumonia is the most common in adults. Pneumonia results in irritation around the ?sacs?, also known as alveoli of the lungs, which causes the alveoli to fill with pus, resulting in breathing issues. PCV13 protects against the 13 kinds of pneumococcal bacteria which cause the most severe illness among children and adults. It is suggested for routine use among children that are 5 years or younger and adults 65 years of age and older. It is also suggested to help prevent pneumococcal disease in individuals through 64 years of age with medical conditions that place them at increased risk for pneumococcal disease. Development of protein-based combination pneumococcal vaccines is expected to offer lucrative opportunities for the expansion of this market during the forecast period.
Based on Vaccine Type, the market is segmented into Pneumococcal conjugate vaccine (PCV) and Pneumococcal polysaccharide vaccine (PPSV/PPV). Based on Product Type, the market is segmented into Prevnar 13, Synflorix and Pneumovax23. According to sector, the market is segmented into Public sector and Private sector. Based on Distribution Channel, the market is further segmented into Distribution partner companies, Non-governmental Organizations (NGO) and Government Authorities. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.
Market Segmentation:
By Vaccine Type
By Product Type
By Sector
By Distribution Channel
By Country
Companies Profiled
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.